Characteristics and prognosis of patients with primary metastatic disease vs. recurrent HER2-negative, hormone receptor-positive advanced breast cancer
Background: Patients with first-line metastatic breast cancer (MBC) comprise patients with de novo metastases (dnMBC) or recurrent disease after primary breast cancer (rMBC). This analysis aimed to explore the prognostic value of dnMBC versus rMBC overall and particularly in subgroups according to a...
Saved in:
| Main Authors: | Christina B. Walter, Andreas D. Hartkopf, Alexander Hein, Peter A. Fasching, Hans-Christian Kolberg, Peyman Hadji, Hans Tesch, Lothar Häberle, Johannes Ettl, Diana Lüftner, Markus Wallwiener, Volkmar Müller, Matthias W. Beckmann, Laura L. Michel, Erik Belleville, Hanna Huebner, Sabrina Uhrig, Chloë Goossens, Pauline Wimberger, Carsten Hielscher, Julia Meyer, Christoph Mundhenke, Christian Kurbacher, Rachel Wuerstlein, Michael Untch, Wolfgang Janni, Florin-Andrei Taran, Michael P. Lux, Diethelm Wallwiener, Sara Y. Brucker, Andreas Schneeweiss, Tanja N. Fehm, Carlo Fremd |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-04-01
|
| Series: | Breast |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S0960977625000311 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The impact of physical activity on progression-free and overall survival in metastatic breast cancer based on molecular subtype
by: Philipp Ziegler, et al.
Published: (2024-10-01) -
The efficacy and therapy management of nab-paclitaxel in the real-world setting for patients with advanced breast cancer – the SERAPHINA study
by: Andreas Schneeweiss, et al.
Published: (2025-06-01) -
Real-world utilization of aromatase inhibitors, tamoxifen, and ovarian function suppression in premenopausal patients with early hormone receptor-positive, HER2-negative breast cancer with increased recurrence risk
by: Volkmar Müller, et al.
Published: (2025-06-01) -
Prediction of pathological complete response after neoadjuvant chemotherapy for HER2-negative breast cancer patients with routine immunohistochemical markers
by: Lothar Häberle, et al.
Published: (2025-01-01) -
Current state of surgical treatment for patients with tubular breast type II (a literature review)
by: A. A. Kostenko, et al.
Published: (2021-02-01)